Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Portal Launched to Accelerate and Improve Biomedical Research Funding

By LabMedica International staff writers
Posted on 03 Apr 2016
A new website launched in collaboration with the National Institutes of Health (NIH) will provide new funding opportunities for scientific projects and present an alternative option to the traditional government grant mechanisms.

In an effort to further scientific advancement, NIH and Leidos (Reston, VA, USA), a health, national security and engineering solutions company, now provide the portal OnPAR – Online Partnership to Accelerate Research. More...
OnPAR represents a new funding paradigm that provides a second opportunity for promising unfunded NIH research proposals. Leidos developed the OnPAR processes and website and will manage the overall program.

There is currently a surplus of high-quality biomedical research applications that merit funding through alternative sources. Through the OnPAR public-private partnership, exceptional applications that were not originally funded by NIH will be matched for potential funding with a participating organization's specialized area of interest.

"OnPAR presents another avenue to fund important biomedical research," said Jim Pannucci, Leidos Director, Life Sciences, "The program will revolutionize the scientific funding environment and foster more discoveries at a faster pace to benefit and improve global health."

Research projects will be considered and funded by OnPAR funding organization members based on their specific research priority areas and requirements. For the pilot project, funding organization members include: Adenoid Cystic Carcinoma Research Foundation, Breast Cancer Research Foundation, Children's Tumor Foundation, JDRF, Melanoma Research Alliance, National Alopecia Areata Foundation, and Parent Project Muscular Distropy. These foundations were selected to span different disease areas and varied foundation sizes.

As the program progresses, OnPAR plans to increase its membership to include additional foundations, pharmaceutical companies, and other life sciences funding organizations across varied disease areas. Leidos also foresees expanding the program globally.

Related Links:

Leidos



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.